2017 Clinical practice guidelines for dyslipidemia of Korean children …
ผู้เขียนบทความ : www.ncbi.nlm.nih.gov
รีวิวจากผู้ใช้งาน : 5 ⭐ (21647 คะแนน)
ระดับสูงสุด : 4 ⭐
คะแนนต่ำสุด : 2 ⭐
สรุปเนื้อหาบทความ :
รายละเอียดเนื้อหาเกี่ยวกับ : guideline ไขมัน 2017
- Making articles easier to read in PMC
- Welcome to PubReader!
- 2017 Clinical practice guidelines for dyslipidemia of Korean children and adolescents
- Abstract
- Introduction
- Definition of dyslipidemia
- Screening recommendations
- Management
- 1. Lifestyle change and diets
- 2. Drug therapy
- Conclusion
- Acknowledgments
- Footnotes
- Article information
- Jung Sub Lim
- Eun Young Kim
- Jae Hyun Kim
- Jae-Ho Yoo
- Kyung Hee Yi
- Hyun Wook Chae
- Jin-Ho Choi
- Ji Young Kim
- Il Tae Hwang
- References
- Fig. 1.
- Table 1.
- Table 2.
- Table 3.
- Table 4.
- CHILD 2–LDL (2–21 yr)CHILD 2–TG (2–21 yr)Birth–6 mo6–12 mo12–24 mo2–10 yr11–21 yrConsultConsult with a clinical nutritionist for clinical nutrition treatment for family members.Fat contentExclusively breastfeeding should be done until 6 mo of age.Continue breastfeeding until at least age 12 mo while gradually adding solids : transition to iron-for tified formula until 12 mo if reducing breastfeeding Infants under 12 mo of age should not limit their fat intake without medical indication.Keep total fat at 30% of total calories and saturated fatty acid at 8%–10% of total calories.Keep total fat at 25%–30% of total calories and saturated fatty acid at 8%–10% of total calories.Keep total fat at 25%–30% of total calories and saturated fatty acid at 7% of total calories.If direct breastfeeding is impossible, use a breast pump, and if any breast feeding is not available, iron-fortified infant formula should be fedConsume monounsaturated and polyunsaturated fatty acids up to 20% of the total calories.Consume monounsaturated and polyunsaturated fattyConsume monounsaturated fatty acids up to 10% of the total calories.Cholesterol is limited to less than 300 mg per day.Cholesterol is limited to less than 300 mg per day.Cholesterol is limited to less than 200 mg per day.Avoid trans fatty acids as much as possible.Avoid trans fatty acids as much as possible.Avoid trans fatty acids as much as possible.Change to non-sugar, lowfat milk (containing no fat or 2% fat).Consume nonsugar, low-fat milk.Sugar intake100% juice should be limited to about 120 mL per day, other beverages should not be fed, Encourage waterLimit sugar sweetened beverages intake and encourage water intake.Limit sugar sweetened beverages and encourage water intake.Reduce simple carbohydrate intake and increase complex carbohydrate intake.Consume beverages without simple sugars.OthersEncourage dietary fiber intake from food.Increase fish intake to increase omega-3 fatty acid intake.Recommend consuming fiber-rich natural foods (fruits, vegetables and grains), but do not recommend fiber supplements. Limit refined carbohydrate foods (sugar, white rice, white bread)Expert recommendationsConsult health-care provider about low-fat milk intake after 12 mo of age if a family history of obesity, heart disease, or dyslipidemia is present.In children with familial hypercholesterolemia over 2 yr of age, vegetable sterols or stanols can be taken instead of other fats up to 2 g per day.If obese, also limit caloric intake and increase activity levels.Water-soluble fiber can be added to the low fat, low saturated fatty acid diets which can be added up to 6 g/day for children aged 2–12 yr and up to 12g/day for children aged 12 yr and older.All children are encouraged to engage at 1 hr of moderate physical activity per day, with television viewing, computer use, and cell phone use limited to less than 2 hr.Open in a separate windowCHILD 1, Cardiovascular Health Integrated Lifestyle Diet 1; CHILD 2-LDL, Cardiovascular Health Integrated Lifestyle Diet 2- low density lipoprotein cholesterol; CHILD 2-TG, Cardiovascular Health Integrated Lifestyle Diet 2-triglyceride.Table 5.
- Table 6.
คำค้นหาที่เกี่ยวข้อง :
[PDF] แนวทางเวชปฏิบัติการใช ยารักษาภาวะไขมันผิดปกติ เพื่อป องกัน
ผู้เขียนบทความ : www.thaiheart.org
รีวิวจากผู้ใช้งาน : 4 ⭐ (26508 คะแนน)
ระดับสูงสุด : 4 ⭐
คะแนนต่ำสุด : 3 ⭐
สรุปเนื้อหาบทความ :
รายละเอียดเนื้อหาเกี่ยวกับ : guideline ไขมัน 2017
คำค้นหาที่เกี่ยวข้อง :
[PDF] Lipids – Ministry of Health
ผู้เขียนบทความ : www.moh.gov.sg
รีวิวจากผู้ใช้งาน : 4 ⭐ (28394 คะแนน)
ระดับสูงสุด : 5 ⭐
คะแนนต่ำสุด : 3 ⭐
สรุปเนื้อหาบทความ :
รายละเอียดเนื้อหาเกี่ยวกับ : guideline ไขมัน 2017
คำค้นหาที่เกี่ยวข้อง :
2022 focused update of the 2017 Taiwan lipid guidelines for high risk …
ผู้เขียนบทความ : www.sciencedirect.com
รีวิวจากผู้ใช้งาน : 4 ⭐ (32765 คะแนน)
ระดับสูงสุด : 4 ⭐
คะแนนต่ำสุด : 3 ⭐
สรุปเนื้อหาบทความ :
รายละเอียดเนื้อหาเกี่ยวกับ : guideline ไขมัน 2017
คำค้นหาที่เกี่ยวข้อง :
ผู้เขียนบทความ :
รีวิวจากผู้ใช้งาน : 4 ⭐ (38638 คะแนน)
ระดับสูงสุด : 4 ⭐
คะแนนต่ำสุด : 3 ⭐
สรุปเนื้อหาบทความ :
รายละเอียดเนื้อหาเกี่ยวกับ : guideline ไขมัน 2017
คำค้นหาที่เกี่ยวข้อง :
2018 AHA/ACC/AACVPR/AAPA/ABC …
ผู้เขียนบทความ : www.ahajournals.org
รีวิวจากผู้ใช้งาน : 4 ⭐ (28448 คะแนน)
ระดับสูงสุด : 5 ⭐
คะแนนต่ำสุด : 2 ⭐
สรุปเนื้อหาบทความ :
รายละเอียดเนื้อหาเกี่ยวกับ : guideline ไขมัน 2017
- Login to your account
- OpenAthens/Shibboleth »
- Jump to
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
- You are viewing the most recent version of this article. Previous versions:
- Table of Contents
- Top 10 Take-Home Messages to Reduce Risk of Atherosclerotic Cardiovascular Disease Through Cholesterol Management
- Preamble
- 1. Introduction
- 1.1. Methodology and Evidence Review
- 1.2. Organization of the Writing Committee
- 1.3. Document Review and Approval
- 1.4. Scope of the Guideline
- 1.5. Class of Recommendation and Level of Evidence
- 1.6. Abbreviations
- 2. High Blood Cholesterol and ASCVD
- 2.1. Serum Cholesterol, Lipoproteins, and ASCVD
- 2.1.1. Cholesterol, Lipoproteins, and Apolipoprotein B
- 2.1.2. Cholesterol, LDL-C, and ASCVD
- 2.1.3. LDL-C and Other Risk Factors
- 2.2. Measurements of LDL-C and Non–HDL-C
- Synopsis
- Recommendation-Specific Supportive Text
- 2.3. Measurements of Apolipoprotein B and Lipoprotein (a)
- 2.4. Monitoring Response of LDL-C to Statin Therapy
- 3. Therapeutic Modalities
- 3.1. Lifestyle Therapies
- 3.1.1. Diet Composition, Weight Control, and Physical Activity
- 3.1.2. Lifestyle Therapies and Metabolic Syndrome
- 3.2. Lipid-Lowering Drugs
- 3.2.1. Statin Therapy
- 3.2.2. Nonstatin Therapies
- 3.2.3. Nonstatin Add-on Drugs to Statin Therapy
- 4. Patient Management Groups
- 4.1. Secondary ASCVD Prevention
- Synopsis
- Recommendation-Specific Supportive Text
- 4.2. Severe Hypercholesterolemia (LDL-C ≥190 mg/dL [≥4.9 mmol/L])
- Synopsis
- Recommendation-Specific Supportive Text
- 4.3. Diabetes Mellitus in Adults
- Synopsis
- Recommendation-Specific Supportive Text
- 4.4. Primary Prevention
- 4.4.1. Evaluation and Risk Assessment
- 4.4.1.1. Essential Process of Risk Assessment
- 4.4.1.2. Pooled Cohort Equations
- 4.4.1.3. Risk-Enhancing Factors
- 4.4.1.4. Coronary Artery Calcium
- 4.4.2. Primary Prevention Adults 40 to 75 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.7 to 4.8 mmol/L)
- Synopsis
- Recommendation-Specific Supportive Text
- 4.4.3. Monitoring in Response to LDL-C–Lowering Therapy
- Recommendation-Specific Supportive Text
- 4.4.4. Primary Prevention in Other Age Groups
- 4.4.4.1. Older Adults
- Synopsis
- Recommendation-Specific Supportive Text
- 4.4.4.2. Young Adults (20 to 39 Years of Age)
- 4.4.4.3. Children and Adolescents
- Synopsis
- Recommendation-Specific Supportive Text
- 4.5. Other Populations at Risk
- 4.5.1. Ethnicity
- Synopsis
- 4.5.2. Hypertriglyceridemia
- Synopsis
- Recommendation-Specific Supportive Text
- 4.5.3. Issues Specific to Women
- Synopsis
- Recommendation-Specific Supportive Text
- 4.5.4. Adults With CKD
- Synopsis
- Recommendation-Specific Supportive Text
- 4.5.5. Adults With Chronic Inflammatory Disorders and HIV
- Synopsis
- Recommendation-Specific Supportive Text
- 5. Statin Safety and Statin-Associated Side Effects
- Synopsis
- Recommendation-Specific Supportive Text
- 6. Implementation
- Synopsis
- Recommendation-Specific Supportive Text
- 7. Cost and Value Considerations
- 7.1. Economic Value Considerations: PCSK9 Inhibitors
- 8. Limitations and Knowledge Gaps
- 8.1. Randomized Controlled Trials
- 8.2. Risk Assessment
- 8.2.1. Continuing Refinement of PCE
- 8.2.2. Improvement in Lifetime Risk Estimate
- 8.2.3. Refinement of Clinician–Patient Risk Discussion
- 8.2.4. Monitoring and Adjustment of Treatment
- 8.2.5. Prognostic Significance of CAC
- ACC/AHA Task Force Members
- Presidents and Staff
- American College of Cardiology
- American College of Cardiology/American Heart Association
- American Heart Association
- Footnotes
- References
- Author Relationships With Industry and Other Entities (Relevant)—2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol* (August 2018)
- Reviewer Relationships With Industry and Other Entities (Comprehensive)—2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (August 2018)
- Article Information
- Metrics
- AHA Journals
- AHA Journals
- Journal Information
- Journal Information
- Subjects
- Subjects
- Features
- Features
- Resources & Education
- Resources & Education
- For Authors & Reviewers
- For Authors & Reviewers
- ABOUT US
- OUR SITES
- TAKE ACTION
- ONLINE COMMUNITIES
คำค้นหาที่เกี่ยวข้อง :
AACE and EAS Lipid Guidelines – American College of Cardiology
ผู้เขียนบทความ : www.acc.org
รีวิวจากผู้ใช้งาน : 4 ⭐ (38465 คะแนน)
ระดับสูงสุด : 4 ⭐
คะแนนต่ำสุด : 1 ⭐
สรุปเนื้อหาบทความ :
รายละเอียดเนื้อหาเกี่ยวกับ : guideline ไขมัน 2017
- AACE and EAS Lipid Guidelines
- Expert Analysis
- You must be logged in as a member to save to your library.
- Tools & Resources
- Similar Articles from ACC.org
- Heart House
คำค้นหาที่เกี่ยวข้อง :